Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
about
Tumour biomarkers: homeostasis as a novel prognostic indicatorBiomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and othersRole of Deficient Mismatch Repair in the Personalized Management of Colorectal CancerEpigenetic Biomarkers in Colorectal Cancer.The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis.KRAS testing and first-line treatment among patients diagnosed with metastatic colorectal cancer using population data from ten National Program of Cancer Registries in the United States.The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis.Epigenetic dysregulation of brainstem nuclei in the pathogenesis of Alzheimer's disease: looking in the correct place at the right time?Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research.Clinicopathologic parameters associated with postoperative complications and risk factors for tumor recurrence and mortality after tumor resection of patients with colorectal cancer.Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease.Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women.The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma.The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis.Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer.Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients.DNA hypomethylation of CBS promoter induced by folate deficiency is a potential noninvasive circulating biomarker for colorectal adenocarcinomas.Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts.Colorectal Cancers: An Update on Their Molecular Pathology.Subcellular proteomics analysis of different stages of colorectal cancer cell lines.Polypeptide-GalNAc-T6 expression predicts better overall survival in patients with colon cancer.miR-888 functions as an oncogene and predicts poor prognosis in colorectal cancer.Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy
P2860
Q28069898-13AF9AAF-90BE-4795-9C40-3C4FB8DB91FDQ28072468-63342E68-7966-4ACF-8C93-9873DBBB02A0Q28080176-855FA977-FEF8-4DC9-A868-A0FE03AC026BQ30240778-8775928F-536C-4D65-A47E-24976C871BF3Q33591665-8A254471-8E53-4774-A3CC-64F388FB831FQ33803490-3AAEA1A0-5824-446F-8DCF-053E83E2C8D5Q36261529-DC1E08E6-EAA9-4D8D-AC6E-EF5DE796D523Q37590630-1E49B130-A73D-424F-A62C-4C8436A1FA59Q38377842-6B1B2ADF-3498-42B4-A4D2-215AD2AFF087Q38677921-C1CBC930-A3BE-46D2-823C-DF8CBFFD1CDEQ38779462-7C78E517-EC3A-4E97-9FAF-D58BB68EC3BDQ40423175-DE4E403F-AA06-4C33-B9C8-E1E3519EB4EEQ41582512-58EA9363-7E80-4FD5-AEA1-4BB7FA510E11Q41593315-0AB341AC-45DC-48AB-9A8E-665D7A2EEAFFQ41608501-E6649F45-4A5A-486A-880A-757CEB0942C5Q41611412-9CD9BC34-E536-4335-A445-B12D5F6AA694Q41612795-518ED084-6DC6-44F8-8AE7-F18CCFB51CB6Q47118009-1B3A9596-F940-4F9A-917C-0C56F59B4611Q48182864-A36CD52F-F4DA-4DE3-B26C-83387E91A67BQ51445383-5556D51D-F9B5-401F-9B3D-5E14167C7053Q55284634-91132FF1-914F-43D8-B1DD-FFA38F1EEF73Q55310838-38852DFD-6B97-4CB6-B0AE-3521F54530D0Q58762177-A5D62A1F-9B2E-46A1-BC1E-1EC8DE73F2BB
P2860
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
@ast
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
@en
type
label
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
@ast
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
@en
prefLabel
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
@ast
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
@en
P2860
P1476
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer
@en
P2093
Frank A Sinicrope
Koichi Okamoto
P2860
P304
P356
10.1016/J.CGH.2016.02.008
P407
P577
2016-02-09T00:00:00Z